|
|
King Fahd Armed Forces
Hospital begins trial of new
bioadaptive angioplasty
procedure
(Jeddah, Saudi
Arabia) - Mumtada
King Fahd Armed Forces
Hospital is first in the
Kingdom of Saudi Arabia to
begin clinical research and
now offer a new type of
angioplasty procedure with
the DynamX bioadaptor
implant, an innovation
beyond stents designed to
restore vessel function. The
bioadaptor is a transforming
implant that, after the
period of healing, unlocks
and allows the artery to
pulse and function more
naturally in response to a
patient’s exertion and
heart’s changing needs. More
normal artery motion and
expansion help the artery
restore its healthy function
and reduce the risks of
secondary adverse events
such as heart attacks or
repeat procedures. The new
procedure is being offered
to patients under the
leadership of Dr. Mirvat
Alasnag, Head of
Catheterization Lab, Dr.
Khalid Al Shaibi, Director
of Cardiac Center, and Dr.
Waqar Ahmed, Interventional
Cardiologist, Dr.Salem
Assiri, Interventional
Cardiologist, and Dr. Sultan
AlOtaibi, Interventional
Cardiologist.
“We are
pleased to offer bioadaptive
angioplasty at King Fahd
Armed Forces Hospital to
patients suffering from
coronary artery disease, and
especially for those who are
younger and seek to reclaim
an active lifestyle,” said
Dr. Mirvat Alasnag, MD, Head
of the Catheterization
Laboratory at the King Fahd
Armed Forces Hospital in
Jeddah, Saudi Arabia. King
Fahd Armed Forces Hospital,
one of the premier hospitals
and clinical research
centers, is also
participating in the global
BIO-RESTORE post-market
registry for bioadaptor to
generate diverse, in-market
experience, specifically in
Saudi patients.
The
bioadaptor is a metallic
coronary device that is
implanted via a minimally
invasive angioplasty
procedure. It is designed to
provide dynamic vessel
support and establish
adaptive hemodynamic
modulation of the artery,
enabling vessel function and
motion and increased blood
flow. It consists of three
thin metal alloy helical
strands held together
temporarily by a
bioabsorbable coating to
provide strength when
opening artery blockage.
Unlike traditional stents,
after the period of healing
and coating resorption in
the first six months, the
bioadaptor unlocks and the
helical strands separate
thereby uncaging the vessel
and establishing more
natural and dynamic support
of artery motion and
function.
Bioadaptors
can also expand slowly over
time along with the artery
in order to maintain good
blood flow. Recent findings
also show stabilization and
even shrinking of plaque
volume in arteries treated
with bioadaptors.
Coronary artery disease
(CAD) is the most common
form of heart disease in the
world and a leading cause of
death. It is caused by a
buildup of fatty deposits
and other substances in the
walls of the arteries that
supply blood to the heart
and other parts of the body.
Over time, the buildup
causes the inside of the
arteries to stiffen and
narrow, and lose their
natural functions, which can
partially or totally block
the flow of blood and
nutrients to the heart.
Chest pain is the most
common symptom of CAD. For
many people, a heart attack
is the first sign that they
have CAD.
PRINT
THIS ARTICLE
|
